vidal_kathi_sv_color_cropped-2-
23 June 2022Big Pharma

Vidal issues non-binding guidance on Fintiv denials

The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the  US Patent Trial and Appeal Board (PTAB) when declining to review a patent’s validity.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
6 September 2022   Mylan and Edwards Lifesciences argue that the controversial rule safeguards poor-quality patents | US v Arthrex conferred increased authority to Vidal over PTAB decisions.
Biotechnology
2 March 2023   Boehringer Ingelheim challenged university patent | Board must provide more details on ruling.

More on this story

Americas
6 September 2022   Mylan and Edwards Lifesciences argue that the controversial rule safeguards poor-quality patents | US v Arthrex conferred increased authority to Vidal over PTAB decisions.
Biotechnology
2 March 2023   Boehringer Ingelheim challenged university patent | Board must provide more details on ruling.

More on this story

Americas
6 September 2022   Mylan and Edwards Lifesciences argue that the controversial rule safeguards poor-quality patents | US v Arthrex conferred increased authority to Vidal over PTAB decisions.
Biotechnology
2 March 2023   Boehringer Ingelheim challenged university patent | Board must provide more details on ruling.